The Important Role of N6-methyladenosine RNA Modification in Non-Small Cell Lung Cancer

Abstract

N6-methyladenosine (m6A) is one of the most prevalent epigenetic modifications of eukaryotic RNA. The m6A modification is a dynamic and reversible process, regulated by three kinds of regulator, including m6A methyltransferases, demethylases and m6A-binding proteins, and this modification plays a vital role in many diseases, especially in cancers. Accumulated evidence has proven that this modification has a significant effect on cellular biological functions and cancer progression; however, little is known about the effects of the m6A modification in non-small cell lung cancer (NSCLC). In this review, we summarized how various m6A regulators modulate m6A RNA metabolism and demonstrated the effect of m6A modification on the progression and cellular biological functions of NSCLC. We also discussed how m6A modification affects the treatment, drug resistance, diagnosis and prognosis of NSCLC patients.

DNASE1L3 as a Novel Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma Based on Data Mining

“…As the most abundant mRNA modification, m6A is involved in the regulation of the occurrence and development of tumors by controlling the expression of key genes, which has become the focus of research in recent years ( Zhao et al, 2020 ). Previous studies have reported that abnormal m6A methylation modification may impact the development of lung cancer ( Cheng et al, 2021 ). Our result showed that there are nine m6A-related regulators that were differentially expressed between high- and low-DNASE1L3 expression of LUAD.…”

Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer

“…The m 6 A modification of RNA, mediated by demethylases, methyltransferases, and m 6 A-binding molecules, influences the progress of NSCLC by affecting the target RNA splicing, translation, decay, and nuclear export. It has been recommended that the influence of m 6 A modification on the prognosis of NSCLC patients is a double-edged sword, indicating m 6 A modification has both promotive and inhibitory effects on progress of NSCLC ( 173 ). CircRNAs are a class of conserved single-stranded RNA molecules derived from intronic or exonic sequences by back-splicing of precursor mRNA, and have been described to have effects on microRNA sponges, regulators of gene splicing and transcription, RNA-binding protein sponges, and protein/peptide translators ( 174 ).…”

New insights into the central sympathetic hyperactivity post‐myocardial infarction: Roles of METTL3‐mediated m6A methylation

“…21 However, little is known about the precise mechanisms of the post-transcriptional regulation of TLR4 expression regulation in the PVN post-MI. N6-methyladenosine (m 6 A) is the most abundant mRNA and epigenetic modification 22,23 that occurs at the post-transcriptional level in mammals. m 6 A is installed onto target mRNA through m 6 A regulators which include the m 6 A methyltransferase complex (METTL3, METTL14, WTAP, VIRMA, RBM15 and ZC3H13) 24 and is enriched near the stop codon, 3′-untranslated region (3′UTR) 25 and long internal exon, primarily occurring in the RRACH sequence (where R = G or A; H = A, C or U) of mRNA.…”